Prior selective internal radiotherapy/hepatic arterial yttrium therapy, at any time
Prior gamma knife, stereotactic radiosurgery, or other focal high-dose radiotherapy is allowed but the subject must have either histopathologic confirmation of recurrent tumor, or new enhancement on MRI outside of the radiotherapy treatment field
No more than  prior regimens for large cell component (e.g. one induction and two salvage therapies); monoclonal antibody alone or involved field/involved site radiotherapy do not count as lines of therapy
Patients may have received prior radiotherapy
Patients who have had any prior radiotherapy to the treatment site(s)
Prior cranial or spinal radiotherapy
Cohort B Safety Run-In (Ribociclib + PDR + Fulvestrant): Prior radiotherapy;\r\n* Participants may have received radiotherapy for palliative purposes but must have completed treatment >=  days prior to first dose of study treatment and not be experiencing > grade  treatment related toxicities
Expansion Cohort B (Ribociclib + PDR + Fulvestrant): Prior radiotherapy:\r\n* Participants may have received radiotherapy for palliative purposes but must have completed treatment >=  days prior to first dose of study treatment and not be experiencing grade >  treatment-related toxicities
Has cSCC that is amenable to surgical resection, local control with radiotherapy, or local control with a combination of surgery and radiotherapy, or chemoradiotherapy.
Patients who have received prior radiotherapy to all areas of current active disease are ineligible
Patients with HGG: Have previously received radiotherapy and temozolomide with a maximum of  prior relapses on treatment
INCLUSION CRITERIA FOR STRATUM C: Patients must have received prior radiotherapy and/or chemotherapy with the following exceptions:\r\n* Patients with secondary CNS cancers after a previous medical problem/malignancy who cannot receive full dose of radiotherapy (>  Gy) as long as they meet all other eligibility criteria\r\n* Patients with progressive low-grade gliomas and CMMRD or Lynch syndrome\r\nPatients must have recovered from the acute treatment related toxicities (defined as =< grade  if not defined in eligibility criteria) of all prior chemotherapy, immunotherapy or radiotherapy prior to entering this study; there is no upper limit to the number of prior therapies that is allowed
Possibility of a curative local treatment (surgery and/or radiotherapy)
Prior whole brain radiotherapy.
The metastases have been treated by surgery and/or radiotherapy.
Requires prohibited treatment (i.e., non-protocol specified anticancer pharmacotherapy, surgery or conventional radiotherapy for treatment of malignant tumor). Limited field single dose radiotherapy for pain palliation would be allowed.
Any prior radiotherapy to the lung
Any prior radiotherapy to the neck
Prior mediastinal radiotherapy
No prior cytotoxic chemotherapy; prior therapy with single-agent rituximab is permitted; prior involved-field radiotherapy to symptomatic nodal sites of involvement is also permitted
Patient must be selected for standard temozolomide chemotherapy to be administered with radiotherapy
Conventional or stereotactic pituitary radiotherapy any time in the past
More than one prior course of radiotherapy or prior prescription doses exceeding  Gy to target volumes
Patients who require immediate surgical or radiotherapy interventions
Disease that can be encompassed within a radical radiotherapy treatment volume
Residual areas of limited disease should be considered for radiotherapy after and not prior to transplantation
Patients must have received prior treatment with focal radiotherapy as part of initial treatment for DIPG and had their last dose at least  weeks prior to and no later than  weeks from the first CED treatment with liposomal irinotecan; standard focal radiation therapy will include  to  Gy by external beam radiotherapy to the brainstem
Patient who has had any prior radiotherapy to the treatment site(s)
Prior radiation that precludes delivery of hypofractionated radiotherapy
Prior peptide-receptor radiotherapy (PRRT)
Prior radiotherapy to the mediastinal/pericardial region
Salvage therapy that includes involved field radiotherapy
Completion of any prior radiotherapy (Cohort C)
Prior selective internal radiotherapy/hepatic arterial yttrium therapy, at any time
Must have previously untreated lymphoma; a short (<  week) course of steroids for symptom palliation is permitted; prior involved field radiotherapy for symptom palliation is permitted as long as there is measurable disease outside the radiation port; if radiotherapy has been given, there should be at least  days between last treatment and beginning of protocol therapy
At least  days have passed since completing radiotherapy (exception for radiotherapy: at least  days since completing a single fraction of =<  cGy to a restricted field or limited-field radiotherapy to non-marrow bearing area such as an extremity or orbit) at the time of registration
Prior whole brain radiotherapy or conventional external beam radiotherapy
Prior cranial radiotherapy within  days of months of trial enrollment or prior SRS at any time to any lesion to be treated on protocol
Prior history of pseudoprogression or radionecrosis from cranial radiotherapy
Planning to undergo standard preoperative radiotherapy
Prior radiotherapy that precludes the proposed treatment with hypofractionated radiotherapy
Prior courses of TSEBT (Note: localized skin-directed radiotherapy is allowed if administered at least  weeks prior to initiation on study).
Prior radiotherapy to a dose of >=  Gy
Prior radiotherapy is allowed
Received prior hemibody external radiotherapy
Primary lung cancer or metastatic disease to the lungs to be treated with either conventionally-fractionated radiotherapy (CFRT) or hypo-fractionated stereotactic ablative radiotherapy (SABR)
A history of prior radiotherapy that precludes delivery of hypofractionated radiotherapy
Patients who have received prior radiotherapy at or adjacent to the primary tumor bed
An interval of >=  months since completion of fractionated radiotherapy
No prior radiotherapy to the brain
Prior whole brain radiotherapy
Predominance of disease that is amenable to radiotherapy
Participants who have had any prior cranial radiotherapy
Prior radiotherapy to the paranasal sinus region or the upper neck (i.e., prior radiotherapy to another disease site is acceptable).
Prior radiotherapy that overlaps with planned radiotherapy portal
interval of ?  months following radiotherapy + TMZ;
Prior focal radiotherapy within  months of screening.
Prior radiotherapy
Patients are excluded if they have been treated with whole brain radiotherapy within the prior  months.
\Study entry\ is defined as the date of informed consent. Patients who received investigational therapy (agents that are not FDA approved), monoclonal antibody such as bevacizumab or cetuximab, or who received radiotherapy to the skull, spine, thorax or pelvis within  days of entry into the protocol. Patients are permitted to have received palliative radiotherapy to an extremity provided at least  days has elapsed since completion of therapy, provided the patient received no more than  radiotherapy fractions and a dose no higher than  Gy to that site, and provided skull, spine, thorax or pelvis were not in the radiotherapy field.
Requirement for systemic chemotherapy: all stages except IA (not bulky disease), if involved field is considered radiotherapy (RT) curative
Subjects with no previous radiotherapy treatment must have a consultation with a radiation oncologist or providers must have a discussion in the context of Neuro-Oncology Tumor Board within  days prior to start of IA/BBBD chemotherapy to determine the need for radiotherapy prior to or after IA/BBBD
Patients must have had no prior radiotherapy to tumor-involved sites
Any prior radiotherapy to the neck
No prior cranial radiotherapy will be permitted
Prior cranial radiotherapy
The disease must be considered to be potentially curable by combined radiotherapy and cisplatin based chemotherapy
Patients with para-aortic nodal disease or who require extended field radiotherapy beyond the pelvis
Residual areas of limited disease should receive radiotherapy following and not prior to transplantation
Prior radium- dichloride or hemibody external radiotherapy
Participants must have V (volume of lung to receive  Gy radiotherapy according to simulation) < %.
Recovery from primary local surgical treatment, radiotherapy or orchiectomy
Radiotherapy within the last  days prior to the first RO infusion with the exception of limited-field palliative radiotherapy.
Serious medical co-morbidities precluding radiotherapy
Patients must have one of the following biopsy proven gynecological cancer and a decision to treat with radiotherapy and concurrent cisplatin chemotherapy (RT-CT)\r\n* Newly diagnosed epithelial carcinoma of the cervix, cTB-B, N/, M/\r\n** Patient may have small volume metastatic disease in para-aortic or supraclavicular lymph nodes or at other metastatic sites as long as, in the best judgment of the treatment team, a radical course of pelvic radiotherapy is warranted to assure local disease control\r\n* Newly diagnosed epithelial carcinoma of the upper / vagina, T-, N/, M/\r\n** Patient may have small volume metastatic disease in para-aortic or supraclavicular lymph nodes or at other metastatic sites as long as, in the best judgment of the treatment team, a radical course of pelvic radiotherapy is warranted to assure local disease control\r\n* Newly diagnosed endometrioid adenocarcinoma of the uterus, cT-, N/, M unsuitable for primary surgery because of the extent of local disease; these patients are eligible if a prior decision has been made to treat radically with neoadjuvant chemoradiation followed by surgery or further radiotherapy (including brachytherapy) depending on response\r\n* Central pelvis or sidewall recurrence of epithelial carcinoma of the cervix of endometrioid adenocarcinoma of the uterus after previous surgery without previous pelvic radiotherapy
Patients requiring para-aortic radiotherapy
Completion of adjuvant radiotherapy according to standard guidelines (e.g. AGO Mamma, NCCN) is strongly recommended. If radiotherapy is not performed the reason for this needs to be documented in the eCRF.
Newly diagnosed participants who are considered appropriate candidates for comprehensive multimodality treatment (involving surgery and/or external beam radiotherapy or chemo radiotherapy).
Prior radiotherapy is allowed
Treatment-free for at least  months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC
Prior stereotactic radiotherapy;
Prior treatment with radiotherapy is allowed.
Patients diagnosed with DIPG: any variances in the radiotherapy dose within % of the current standard dose ( Gy) will be discussed with the Sponsor-Investigator to confirm eligibility prior to study enrollment
Patients diagnosed with HGG: any variances in the radiotherapy dose within % of the current standard dose (. Gy) will be discussed with the Sponsor-Investigator to confirm eligibility prior to study enrollment.
Patients diagnosed with primary spinal tumors any variances in the radiotherapy dose within % of the current standard dose ( Gy) will be discussed with the Sponsor-Investigator to confirm eligibility prior to study enrollment.
For participants with DLBCL: preplanned consolidative radiotherapy
Prior therapies: BTK inhibitor, radiotherapy, radiotherapy in the adjuvant setting, or cytotoxic chemotherapy for primary disease of pancreatic adenocarcinoma.
Radiotherapy
Prior systemic therapy or radiotherapy for MPM; local radiotherapy of noncurative intent (ie, for prevention of instrument-tract recurrence and/or symptom control) is permitted
Prior history of whole brain radiotherapy (only applicable for AZD BM expansion)
Radiotherapy (except extremities) within  months prior to baseline imaging
Patient has received no prior treatment with any systemic therapy for the treatment of multiple myeloma\r\n* Prior treatment of hypercalcemia or spinal cord compression with corticosteroids does not disqualify the patient (the dose should not exceed the equivalent of  mg of dexamethasone in a  week period)\r\n* Patients may receive corticosteroids for the management of their multiple myeloma that should not exceed the equivalent of  mg of dexamethasone in a  week period and should be stable for at least  days prior to the initiation of therapy \r\n* Bisphosphonates are permitted\r\n* Patients treated with local radiotherapy with or without concomitant exposure to steroids, for pain control or management of cord/nerve root compression, are eligible; two weeks must have lapsed since last date of radiotherapy, which is recommended to be a limited field; patients who require concurrent radiotherapy should have entry to the protocol deferred until the radiotherapy is completed
Received prior hemibody external radiotherapy
Prior hemi-body external radiotherapy; subjects who received other types of prior external radiotherapy are allowed provided that bone marrow function is assessed and meets the protocol requirements for hemoglobin, ANC, and platelets
Radiotherapy to >=  sites at the same time within  week prior to the first day of treatment
Prior systemic radiotherapy and hemibody external radiotherapy
Prior systemic radiotherapy and hemibody external radiotherapy
COHORT B: Prior radiotherapy to the prostate (adjuvant or salvage radiotherapy) is allowed
BCC/SCC in region adjacent to or overlapping with region of prior radiotherapy
BREAST RADIOTHERAPY:
Radiotherapy to >=  sites at the same time within  week prior to signing consent
Has received or is in the process of completing a course of definitive radiotherapy of at least  Gray (Gy) with concurrent temozolomide (patient may be registered before completing radiotherapy as long as it is anticipated that s/he will complete at least  Gy)
Received prior salvage therapy, including radiotherapy
Patient may have any prior therapy allowed aside from having had prior radiotherapy to the treatment site
Prior radiotherapy or biologic therapy
The patient is a candidate for definitive external beam radiotherapy; the patient has had no prior radiotherapy to the region of study; the patient has no inflammatory bowel disease, active collagen vascular or connective tissue disorders, and no other medical or social contraindications to radiotherapy, as determined by a participating radiation oncologist
Patients treated with local radiotherapy with or without concomitant exposure to steroids, for pain control or management of cord/nerve root compression, are eligible; one week must have lapsed since last date of radiotherapy, which is recommended to be a limited field and from start of protocol therapy; patients who require concurrent radiotherapy should have entry to the protocol deferred until the radiotherapy is completed and one week have passed since the last date of therapy and from start of protocol therapy
Prior treatment with approximately  Gy of radiotherapy
Prior cranial radiotherapy
Women who have undergone simple or radical hysterectomy prior to radiotherapy
TREATED PRIMARY - PRIOR RADIOTHERAPY:
Patient may have any prior therapy allowed aside from having had prior radiotherapy to the treatment site
Patient who has had any prior radiotherapy to the treatment site(s)
Use of amifostine or pilocarpine before and during radiotherapy is not allowed
No prior radiotherapy to the brain
Subject has received radiotherapy within  week prior to the first dose of study drug. If the subject received radiotherapy >  week prior to study treatment, the irradiated lesion cannot be the only lesion used for evaluating response.
Prior selective internal radiotherapy/hepatic arterial yttrium therapy, at any time
Prior radiotherapy to disease sites is allowed with certain protocol-defined restrictions.
interval of at least  months following initial radiotherapy and temozolomide
Prior focal radiotherapy
Unresected tumour prior to chemo-radiotherapy (CRT)
Treated with local radiotherapy
Participants who have had chemotherapy or radiotherapy for intrahepatic cholangiocarcinoma
Extensive prior radiotherapy.
Prior chemotherapy or radiotherapy (other than limited, emergent radiotherapy for treatment of eg. spinal cord compromise or threatened airway)
No prior radiotherapy
Prior cranial radiotherapy
Prior cranial radiotherapy or radiotherapy to the head and neck where potential field overlaps would exist
Having finished radiotherapy at least two months ago
Receiving chemotherapy or radiotherapy at the time of study enrollment. Anti-her directed therapy is not exclusionary.
Whole-brain radiotherapy (WBRT) <  days from the anticipated start of nintedanib/placebo administration
Will receive radiotherapy of cranium within one week prior to or during the study
Must have received and completed radiotherapy with or without chemotherapy for head and neck cancer; time from completion of radiotherapy to registration must be at least  months and up to a maximum of  year
Patient has received prior radiotherapy to the involved breast
Participants who have had prior cHL-directed chemotherapy or radiotherapy
Utilization of amifostine during radiotherapy
Patient must not have history of prior cranial radiotherapy
Receiving radiotherapy or chemoradiation
Be receiving concurrent radiotherapy or interferon.
Prior radiotherapy that overlaps with radiation fields
Radiotherapy treatment prior to the first veledimex dose:
Subject receiving radiotherapy alone as treatment for his/her haematologic malignancy.
Concurrent radiotherapy prior to the performance of both CMR studies, however consolidative radiotherapy after the completion of DOX and after the acquisition of the second CMR study is acceptable
No prior malignancy treated with chemotherapy or mediastinal radiotherapy
Willingness to undergo radiotherapy.
History of hemibody external radiotherapy as assessed by medical record review
No prior history of breast radiotherapy that will prevent the use of radiotherapy for the present DCIS
A plan to treat with radiotherapy
